BETTERLIFE PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0872 USD | +4.62% |
|
-8.30% | +81.88% |
| May. 03 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
| May. 01 | BetterLife Pharma Advances IND-enabling Studies For BETR-001 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 13.32M |
|---|---|---|---|---|---|
| Net income 2022 | -12M | Net income 2023 | -9M | EV / Sales 2022 | - |
| Net Debt 2022 | 139K | Net Debt 2023 | 71.69K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.26
x | P/E ratio 2023 |
-1.36
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.36% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +4.62% | ||
| 1 week | -8.30% | ||
| Current month | +5.31% | ||
| 1 month | +20.08% | ||
| 3 months | +20.41% | ||
| 6 months | +85.74% | ||
| Current year | +81.88% |
1 week
0.08
0.10
1 month
0.070.10
Current year
0.050.10
1 year
0.030.10
3 years
0.030.55
5 years
0.035.40
10 years
0.0124.60
| Managers | Title | Age | Since |
|---|---|---|---|
Ahmad Doroudian
CEO | Chief Executive Officer | 63 | 07-09-16 |
Moira Ong
DFI | Director of Finance/CFO | 49 | 10-12-25 |
| Chief Operating Officer | 67 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ahmad Doroudian
CEO | Chief Executive Officer | 63 | 07-09-16 |
Robert Metcalfe
BRD | Director/Board Member | 84 | 20-01-20 |
Wolfgang Renz
BRD | Director/Board Member | 54 | 15-02-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.0872 | +4.62% | 26,607 |
| 24-05-09 | 0.0834 | -7.33% | 13,868 |
| 24-05-08 | 0.09 | -6.44% | 94,115 |
| 24-05-07 | 0.0962 | +3.44% | 178,010 |
| 24-05-06 | 0.093 | -2.35% | 59,400 |
Delayed Quote OTC Markets, May 10, 2024 at 03:59 pm EDT
More quotes
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Companyâs subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.
Calendar
2024-05-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +81.88% | 10.12M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +0.12% | 22.25B | |
| -13.14% | 22.09B | |
| -7.56% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- BETRF Stock